News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
282,577 Results
Type
Article (15433)
Company Profile (286)
Press Release (266858)
Section
Business (84700)
Career Advice (194)
Deals (14770)
Drug Delivery (36)
Drug Development (51780)
Employer Resources (31)
FDA (6228)
Job Trends (5412)
News (153630)
Policy (11031)
Tag
Academia (926)
Alliances (22917)
Alzheimer's disease (785)
Antibody-drug conjugate (ADC) (70)
Approvals (6220)
Artificial intelligence (90)
Bankruptcy (112)
Best Places to Work (4619)
Biotechnology (234)
Breast cancer (124)
Cancer (1058)
Cardiovascular disease (85)
Career advice (168)
CAR-T (87)
Cell therapy (250)
Clinical research (41654)
Collaboration (406)
Compensation (161)
COVID-19 (1029)
C-suite (106)
Cystic fibrosis (72)
Data (1099)
Diabetes (105)
Diagnostics (1395)
Earnings (31358)
Events (49366)
Executive appointments (339)
FDA (6688)
Funding (384)
Gene editing (72)
Gene therapy (189)
GLP-1 (339)
Government (1102)
Healthcare (6830)
Infectious disease (1075)
Inflammatory bowel disease (100)
IPO (7629)
Job creations (1086)
Job search strategy (151)
Layoffs (197)
Legal (1803)
Lung cancer (157)
Manufacturing (100)
Medical device (2911)
Medtech (2912)
Mergers & acquisitions (7348)
Metabolic disorders (306)
Neuroscience (1084)
NextGen: Class of 2025 (2064)
Non-profit (886)
Northern California (1253)
Obesity (163)
Opinion (99)
Parkinson's disease (87)
Patents (73)
People (26800)
Phase I (14496)
Phase II (19205)
Phase III (12419)
Pipeline (473)
Postmarket research (1032)
Preclinical (6063)
Radiopharmaceuticals (208)
Rare diseases (234)
Real estate (1534)
Regulatory (8951)
Research institute (949)
Series A (76)
Southern California (1118)
Startups (2030)
United States (10028)
Vaccines (184)
Weight loss (94)
Date
Today (11)
Last 7 days (384)
Last 30 days (1606)
Last 365 days (20929)
2025 (1659)
2024 (21102)
2023 (23088)
2022 (28658)
2021 (29488)
2020 (24805)
2019 (17146)
2018 (12451)
2017 (14746)
2016 (12871)
2015 (15841)
2014 (11498)
2013 (8272)
2012 (8331)
2011 (8353)
2010 (8134)
Location
Africa (160)
Asia (17568)
Australia (2979)
California (2854)
Canada (903)
China (258)
Colorado (107)
Connecticut (118)
Delaware (67)
Europe (46784)
Florida (323)
Georgia (84)
Illinois (184)
Indiana (71)
Maryland (374)
Massachusetts (2306)
Minnesota (119)
New Jersey (723)
New York (791)
North Carolina (485)
Northern California (1253)
Ohio (92)
Pennsylvania (543)
South America (232)
Southern California (1118)
Texas (317)
Washington State (280)
282,577 Results for "silence therapeutics plc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
Silence Therapeutics plc today announced the Company will present at the Jefferies Global Healthcare Conference on Thursday, June 6th at 2:30 p.m. ET.
May 30, 2024
·
1 min read
Business
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
Silence Therapeutics plc today announced that Alistair Gray, who has served as an independent member of Silence’s Board of Directors (the “Board”) since 2015, informed the Company that he will retire from the Board, effective May 1, 2024.
April 29, 2024
·
2 min read
Business
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
Silence Therapeutics plc, today reported its financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights.
May 16, 2024
·
7 min read
Business
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
Silence Therapeutics plc today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (“Hansoh”) following the achievement of a second undisclosed milestone related to the first target under the collaboration.
June 24, 2024
·
5 min read
Drug Development
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
Silence Therapeutics plc announced positive results from the ongoing SANRECO Phase 1 repeat dose study of divesiran, a siRNA targeting TMPRSS6, in patients with polycythemia vera.
June 27, 2024
·
9 min read
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
Silence Therapeutics plc today announced the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference.
April 30, 2024
·
1 min read
Business
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
Silence Therapeutics plc today reported its financial results for the full year ended December 31, 2023, and reviewed recent business highlights.
March 13, 2024
·
10 min read
Press Releases
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
November 13, 2024
·
1 min read
Drug Development
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
Silence Therapeutics plc today announced positive topline 48-week data from the ALPACAR-360 phase 2 study of zerlasiran (SLN360) in 178 subjects with baseline lipoprotein(a), or Lp(a), levels at or over 125 nmol/L at high risk of atherosclerotic cardiovascular disease (ASCVD) events.
June 20, 2024
·
5 min read
Drug Development
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”) today announced additional results from the APOLLO phase 1 study of zerlasiran (SLN360) in subjects with baseline lipoprotein(a), or Lp(a), levels at or over 150 nmol/L were published in the Journal of the American Medical Association (JAMA).
April 8, 2024
·
5 min read
1 of 28,258
Next
